




# CHOLINE-DEFICIENT, L-AMINO ACID-DEFINED – HIGH FAT DIET-INDUCED (CDA-HFD) NASH MOUSE MODEL

- The global prevalence of NAFLD sits at ~25%, making it the most common cause of chronic liver disease
  - Manifestation of several conditions associated with metabolic dysfunction
  - Development and progression is complex and multifactorial; poor dietary habits, sedentary lifestyle, environmental factors, genetic factors
- Estimates suggest that the global NASH prevalence is ~5%
  - NAFLD may progress to NASH, which is characterized by steatosis, inflammation with ballooned hepatocytes and fibrosis
  - Greatest risk factor for NAFLD/NASH pathogenesis is fatty liver
- · CDA-HFD is a classic model for NASH induction:
  - L-amino acid diet with 60 kcal% fat, 0.1% methionine, no added choline
  - Methionine deficiency decreases glutathione biosynthesis, leading to oxidative stress and contributing to liver damage
  - Choline deficiency inhibits the synthesis of phosphatidylcholine, leading to lipid accumulation in the liver




ChemPartner has developed and validated a CDA-HFD mouse model, which exhibits non-metabolic associated NASH with progressive fibrosis:

- ✓ Ready to use
- ✓ Cost-effective

- ✓ Non-obese mice
- ✓ Early onset of hepatic steatosis and fibrosis
- ✓ Rapid disease progression
- ✓ Validated endpoints

## STUDY OUTLINE

#### CDA-HFD-INDUCED NASH PRECLINICAL IN VIVO MOUSE MODEL




- Strain
  - Male C57BL/6 mice, 7 weeks on arrival
- Model
  - CDA-HFD (L-amino acid diet with 60 kcal% fat, 0.1% methionine, no added choline; Research Diets Inc #A06071302) – diet fed weeks 0-12
  - Control diet standard rodent chow (PMI Nutrition International; product number 5C02C)


#### **MAJOR READOUTS**


- Body weight
- Liver/body weight ratio
- Blood: AST, ALT and ALP
- Pathology: H&E, Sirius Red and Oil Red staining
- NAFLD activity score (NAS) and fibrosis score


## **KEY MODEL CHARACTERISTICS:**


- ✓ Mice fed continuously on CDA-HFD
- ✓ Diet-induced non-obese mouse model
- ✓ Increased liver/body weight ratio in week 6 and 12
- ✓ Elevated blood aspartate aminotransferase (AST) from week 4 to week 12
- ✓ Elevated blood alanine transaminase (ALT) from week 4 to week 12
- ✓ Elevated blood alkaline phosphatase (ALP) from week 6 to week 12
- ✓ Prophylactic and therapeutic drug efficacy















## HISTOPATHOLOGICAL FEATURES


- ✓ Pale liver
- ✓ Hallmarks of NASH; increased hepatic steatosis, lobular inflammation
- ✓ Significantly increased NAS score from week 6
- ✓ Evidence of lipogenesis
- ✓ Observed fibrosis in the liver tissue of CDA-HFD fed mice











## **SUMMARY**

The CDA-HFD-induced mouse model is a robust and well validated model, offering a non-obese, non-metabolic NASH phenotype, which is simple, reproducible, and technically undemanding.

LEARN MORE AT CHEMPARTNER.COM/SERVICES/BIOLOGY-PHARMACOLOGY